US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Ascentage Pharma Group International - American Depository Shares (NQ:AAPG)

14.61 -0.76 (-4.95%)
Delayed Quote Updated: 3:57 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascentage Pharma Group International - American Depository Shares

< Previous 1 2 Next >
News headline image
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight ↗
Small-cap stocks Ascentage Pharma, Maze Therapeutics, and Pagaya Technologies show improving fundamentals, strong cash positions, and bullish analyst ratings amid shifting investor interest. 
Via MarketBeat
News headline image
Transcript: Ascentage Pharma Group H1 2026 Earnings Conference Call ↗
On Thursday, Ascentage Pharma Group (NASDAQ:AAPG) discussed quarterly financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For... 
Via Benzinga
Topics Earnings
News headline image
Ascentage Pharma Group International H1 Earnings Call Highlights ↗
Ascentage Pharma Group International (NASDAQ:AAPG) reported first-half 2026 revenue growth as it continued investing in global registrational studies for its hematology-oncology pipeline and began... 
Via MarketBeat
Topics Earnings
News headline image
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma to Participate in Three Upcoming Investor Conferences
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma to Participate in Three Upcoming Investor Conferences
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
This Hasbro Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
This Docebo Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 20, 2025 ↗
 
Via Benzinga
News headline image
US Stocks Likely To Open Mixed As Trump Issues Tariff Letters: Experts Peg AI Investments As 'Durable Drivers Of Returns' ↗
U.S. stock futures were fluctuating on Tuesday after trimming gains on Monday. Futures of major benchmark indices were trading mixed. 
Via Benzinga
Topics Artificial Intelligence Government
News headline image
Penguin Solutions, Merit Medical Systems And 3 Stocks To Watch Heading Into Tuesday ↗
 
Via Benzinga
News headline image
Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio? ↗
Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics. 
Via Benzinga
Topics Artificial Intelligence
< Previous 1 2 Next >